Nuvectis Pharma, Inc.
NVCTHealthcare|Biotechnology|US
$20.91
+3.15 (+17.74%)
DCF Value
$1.18
Tangible Book / Share
$4.30
Cash / Share
$4.78
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05873686 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer) | P1 | Active | 140 | Open-label | NXP900 |
| NCT07315113 Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | P1 | Recruiting | 18 | Open-label | NXP900, Osimertinib |
| NCT07784959 Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | ALK Positive, ALK Positive Non-small Cell Lung Cancer | P1 | Recruiting | 54 | Open-label | NXP900, Lorlatinib |
| NCT05226507 A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | Advanced Solid Tumor, Ovarian Cancer | P1 | Terminated | 45 | Open-label | NXP800 |